Off-label use of rituximab for systemic lupus erythematosus in Europe.
about
The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European CountriesSystemic lupus erythematosus: Extent and patterns of off-label use of rituximab for SLE.Characterization of patients with systemic lupus erythematosus who meet the diagnostic criteria for TAFRO syndrome.Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going?Current perspective on rituximab in rheumatic diseases.B Cell-Based Treatments in SLE: Past Experience and Current Directions.
P2860
Off-label use of rituximab for systemic lupus erythematosus in Europe.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Off-label use of rituximab for systemic lupus erythematosus in Europe.
@en
Off-label use of rituximab for systemic lupus erythematosus in Europe.
@nl
type
label
Off-label use of rituximab for systemic lupus erythematosus in Europe.
@en
Off-label use of rituximab for systemic lupus erythematosus in Europe.
@nl
prefLabel
Off-label use of rituximab for systemic lupus erythematosus in Europe.
@en
Off-label use of rituximab for systemic lupus erythematosus in Europe.
@nl
P2093
P2860
P50
P1476
Off-label use of rituximab for systemic lupus erythematosus in Europe.
@en
P2093
Agustín Colodro Ruiz
Alexandre Voskuyl
Annamaria Iuliano
Antoni Castro
Cristina Gonzalez-Echavarri
Danilo Squatrito
Dimitrios Boumpas
Elisa Gremese
Frederic A Houssiau
Gabriella Szücs
P2860
P304
P356
10.1136/LUPUS-2016-000163
P577
2016-09-06T00:00:00Z